[The effect of mosapride on quality of life in functional dyspepsia].
OBJECTIVE
It is unknown whether the prokinetics improve the quality of life in patients with functional dyspepsia. Thus, we evaluate the effect of the mosapride, selective 5-HT4 agonist, on the symptom and life quality of patients with functional dyspepsia using the Nepean dyspepsia index-Korean version (NDI-K), a reliable and validated disease-specific quality of life questionnaire.


METHODS
A single, open trial was performed in 129 patients with functional dyspepsia. Patients were received mosapride 5 mg t.i.d before each meal for 4 weeks. The symptoms and quality of life were measured with the NDI-K at baseline and 4 weeks. The responsiveness of the NDI-K was evaluated by correlation with symptom scores.


RESULTS
All the 15 symptom scores and the dyspepsia score decreased after treatment (p<0.05). The total symptom score decreased from 60.9 +/- 25.8 to 24.7 +/- 20.4 (p=0.001). Correlations were observed between the total symptom score and the NDI-K score (r=0.47, p=0.001), and between the total symptom score and each score in 5 subscales (r=0.25-0.44, p=0.001). The NDI-K score was significantly increased in the effective group whose dyspepsia score decreased more than 50% of the score at baseline, compared with that of ineffective group. Any significant adverse effect and prolongation of QT interval were not occurred in all patients.


CONCLUSIONS
A prokinetic drug, mosapride improves the symptoms and the quality of life in patients with functional dyspepsia.
Cho
Yu Kyung
YK
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seocho-gu, Seoul, Korea.
Choi
Myung-Gyu
MG
Kim
Se Hee
SH
Lee
In Seok
IS
Kim
Sang Woo
SW
Chung
In-Sik
IS
Lee
Sang Yeol
SY
Choi
Suck Chei
SC
Seol
Sang Young
SY
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011788:Quality of Life; D011795:Surveys and Questionnaires
D001549:Benzamides; D018492:Dopamine Antagonists; D005765:Gastrointestinal Agents; D009025:Morpholines; C062720:mosapride